Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting PI3K/AKT/mTOR network for treatment of leukemia.
Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, Saki N. Bertacchini J, et al. Cell Mol Life Sci. 2015 Jun;72(12):2337-47. doi: 10.1007/s00018-015-1867-5. Epub 2015 Feb 25. Cell Mol Life Sci. 2015. PMID: 25712020 Review.
A-type lamins and signaling: the PI 3-kinase/Akt pathway moves forward.
Marmiroli S, Bertacchini J, Beretti F, Cenni V, Guida M, De Pol A, Maraldi NM, Lattanzi G. Marmiroli S, et al. Among authors: bertacchini j. J Cell Physiol. 2009 Sep;220(3):553-61. doi: 10.1002/jcp.21807. J Cell Physiol. 2009. PMID: 19479937 Review.
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
Bertacchini J, Guida M, Accordi B, Mediani L, Martelli AM, Barozzi P, Petricoin E 3rd, Liotta L, Milani G, Giordan M, Luppi M, Forghieri F, De Pol A, Cocco L, Basso G, Marmiroli S. Bertacchini J, et al. Leukemia. 2014 Nov;28(11):2197-205. doi: 10.1038/leu.2014.123. Epub 2014 Apr 4. Leukemia. 2014. PMID: 24699302
Inhibition of Ras-mediated signaling pathways in CML stem cells.
Bertacchini J, Ketabchi N, Mediani L, Capitani S, Marmiroli S, Saki N. Bertacchini J, et al. Cell Oncol (Dordr). 2015 Dec;38(6):407-18. doi: 10.1007/s13402-015-0248-2. Epub 2015 Oct 12. Cell Oncol (Dordr). 2015. PMID: 26458816 Review.
Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.
Mediani L, Gibellini F, Bertacchini J, Frasson C, Bosco R, Accordi B, Basso G, Bonora M, Calabrò ML, Mattiolo A, Sgarbi G, Baracca A, Pinton P, Riva G, Rampazzo E, Petrizza L, Prodi L, Milani D, Luppi M, Potenza L, De Pol A, Cocco L, Capitani S, Marmiroli S. Mediani L, et al. Among authors: bertacchini j. Oncotarget. 2016 Feb 2;7(5):5521-37. doi: 10.18632/oncotarget.6315. Oncotarget. 2016. PMID: 26575168 Free PMC article.
The Role of HDACs as Leukemia Therapy Targets using HDI.
Ahmadzadeh A, Khodadi E, Shahjahani M, Bertacchini J, Vosoughi T, Saki N. Ahmadzadeh A, et al. Among authors: bertacchini j. Int J Hematol Oncol Stem Cell Res. 2015 Oct 1;9(4):203-14. Int J Hematol Oncol Stem Cell Res. 2015. PMID: 26865932 Free PMC article.
Cross-talk between the CK2 and AKT signaling pathways in cancer.
Ruzzene M, Bertacchini J, Toker A, Marmiroli S. Ruzzene M, et al. Among authors: bertacchini j. Adv Biol Regul. 2017 May;64:1-8. doi: 10.1016/j.jbior.2017.03.002. Epub 2017 Mar 28. Adv Biol Regul. 2017. PMID: 28373060 Review.
46 results